These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21179947)

  • 1. Development and performance evaluation of amphotericin B transfersomes against resistant and sensitive clinical isolates of visceral leishmaniasis.
    Singodia D; Gupta GK; Verma A; Singh V; Shukla P; Misra P; Sundar S; Dube A; Mishra PR
    J Biomed Nanotechnol; 2010 Jun; 6(3):293-302. PubMed ID: 21179947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
    Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
    Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
    Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
    Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies.
    Mudavath SL; Talat M; Rai M; Srivastava ON; Sundar S
    Drug Des Devel Ther; 2014; 8():1235-47. PubMed ID: 25214767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis.
    Italia JL; Kumar MN; Carter KC
    J Biomed Nanotechnol; 2012 Aug; 8(4):695-702. PubMed ID: 22852479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis.
    Khatik R; Dwivedi P; Khare P; Kansal S; Dube A; Mishra PR; Dwivedi AK
    Expert Opin Drug Deliv; 2014 May; 11(5):633-46. PubMed ID: 24606222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.
    Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR
    Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
    Banerjee A; De M; Ali N
    J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis.
    Singh PK; Pawar VK; Jaiswal AK; Singh Y; Srikanth CH; Chaurasia M; Bora HK; Raval K; Meher JG; Gayen JR; Dube A; Chourasia MK
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):1220-1231. PubMed ID: 28780414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
    Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
    Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis.
    Gupta S; Dube A; Vyas SP
    J Drug Target; 2007 Jul; 15(6):437-44. PubMed ID: 17613662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.
    Chaurasia M; Singh PK; Jaiswal AK; Kumar A; Pawar VK; Dube A; Paliwal SK; Chourasia MK
    Pharm Res; 2016 Nov; 33(11):2617-29. PubMed ID: 27401407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
    Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
    Wasan EK; Gershkovich P; Zhao J; Zhu X; Werbovetz K; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    PLoS Negl Trop Dis; 2010 Dec; 4(12):e913. PubMed ID: 21151883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies.
    Rodrigo C; Weeratunga P; Fernando SD; Rajapakse S
    Clin Microbiol Infect; 2018 Jun; 24(6):591-598. PubMed ID: 29138100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.
    Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG
    J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
    Thakur CP; Narayan S; Ranjan A
    Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex.
    Mohamed-Ahmed AH; Seifert K; Yardley V; Burrell-Saward H; Brocchini S; Croft SL
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4608-14. PubMed ID: 23796924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.